Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

The role of AKT isoforms in glioblastoma: AKT3 delays tumor progression.

Authors: Joy, Anna  Kapoor, Manisha  Georges, Joseph  Butler, Lacy  Chang, Yongchang  Li, Chaokun  Crouch, Acacia  Smirnov, Ivan  Nakada, Mitsitoshi  Hepler, James  Marty, Max  Feuerstein, Burt G 
Citation: Joy A, etal., J Neurooncol. 2016 Oct;130(1):43-52. doi: 10.1007/s11060-016-2220-z. Epub 2016 Jul 15.
Pubmed: (View Article at PubMed) PMID:27422127
DOI: Full-text: DOI:10.1007/s11060-016-2220-z

The growth factor receptor/PI3K/AKT pathway is an important drug target in many cancers including Glioblastoma. AKT, a key node in the pathway, has 3 isoforms, AKT1, AKT2 and AKT3. Here we investigate their role in GBM. We find each activated, ser473 phosphorylated isoform is present in some GBMs but expression patterns vary. There is a direct relationship between human GBM patient outcome and both AKT1 and AKT2 mRNA levels, but an inverse relationship with AKT3 mRNA. Furthermore, AKT3 mRNA levels were high in a less aggressive GBM subtype. Overexpressing AKT3 improves survival in a rodent model of GBM and decreases colony forming efficiency, but not growth rate, in glioma cells. Silencing AKT3 slows cell cycle progression in one cell line and increases apoptosis in another. Our studies of AKT3 substrates indicate (1) silencing both AKT2 and AKT3 reduces GSK3 phosphorylation (2) only AKT2 silencing reduces S6 phosphorylation. Since S6 phosphorylation is a marker of mTORC1 activity this indicates that AKT2 activates mTORC1, but AKT3 does not. Our results indicate AKT isoforms have different roles and downstream substrates in GBM. Unexpectedly, they indicate AKT3 delays tumor progression. Therefore strategies that inhibit AKT3 may be unhelpful in some GBM patients.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 13674164
Created: 2018-07-10
Species: All species
Last Modified: 2018-07-10
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.